N/A N=17 Testosterone Replacement Therapy in Advanced Chronic Kidney Disease
Kidney Failure · Kidney Diseases
Primary: Thigh Cross Sectional Area — 58.2 centimeters squared
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=172 Theranova 400 Dialyzer In End Stage Renal Disease (ESRD) Patients
End Stage Renal Disease
Primary: Reduction Ratio of Lambda Immunoglobulin FLC at Week 24 — 32.156; 17.514 percentage ratio
N/A N=274 Theranova Randomized, Controlled, Trial (RCT) in China
Chronic Kidney Failure · Acute Kidney Failure
Primary: Reduction Ratio (RR) of Lambda Free Light Chains (λ FLC) — 36.02; 19.03 Reduction Ratio (%) — p=<0.0001
Phase 3 N=20 A Study of Subcutaneous C.E.R.A. for the Maintenance of Hemoglobin Levels in Participants With Chronic Renal Anemia Not on Dialysis.
Anemia
Primary: Percentage of Participants Maintaining Hb Concentration Within +/-1 Gram Per Deciliter (g/dL) of Their Reference Hb and Between 10.5 to 12.5 g/dL Throughout the Efficacy…
Phase 4 N=2,825 A Study to Assess All-Cause Mortality and Cardiovascular Morbidity in Participants With Chronic Kidney Disease (CKD) on Dialysis and Those Not on Renal Replacement Therapy Receiving Methoxy Polyethylene Glycol-Epoetin Beta (Mircera) or Reference Erythropoietin Stimulating Agents (ESAs)
Chronic Renal Anemia
Primary: Time to Composite of All-Cause Mortality and Non-Fatal Cardiovascular Events (Myocardial Infarction, Stroke) Defined as Time Between First Dose of Study Medication and…
Phase 4 N=184 Treatment Response in Dialysis Anaemia
Anaemia · Haemodialysis
Primary: Haemoglobin Increase of Greater or Equal to 5g/l Following Receipt of Treatment — 53; 61 Participants
Phase 2 N=10 A Study of Autologous Renal Autologous Cell Therapy (REACT) in Patients With Diabetic Chronic Kidney Disease
Type 2 Diabetes Mellitus · Chronic Kidney Disease
Primary: Procedure and/or Product Related Adverse Events — 70.0; 60.0; 30.0; 20.0 percent of participants
Phase 4 N=309 20070360 Incident Dialysis
Chronic Kidney Disease · Secondary Hyperparathyroidism
Primary: Achievement of a ≥ 30% Reduction in Mean PTH From Baseline to During the Efficacy Assessment Phase at Month 6 (Weeks 22 to 26) — 96; 58; 57; 93 participants — p=<0.0001
N/A N=44 Low Dose Thymoglobin in Renal Transplant Patients
Acute Renal Failure
Primary: Rates of Acute Cellular Rejection Between Study Group — 4; 2 Number of rejection — p=<0.05
Phase 3 N=90 Denosumab for Prevention of Osteoporosis in Renal Transplant Recipients
Osteoporosis · Chronic Kidney Disease
Primary: Percent Change in BMD at the Total Lumbar Spine From Baseline to Month 12 — 4.5; -0.3 percent change — p=<0.001
Phase 3 N=140 A Study of Monthly Subcutaneous Continuous Erythropoietin Receptor Activator (CERA) in Predialysis Participants With Chronic Renal Anemia
Anemia
Primary: Percentage of Participants Maintaining Their Mean Hb Concentration Within Plus/Minus (±) 1 Grams Per Deciliter (g/dL) of the Reference Range and Between 10.0 and 12.0…
Phase 3 N=1,124 Acute Renal Failure Trial Network (ATN) Study
Acute Renal Failure
Primary: 60-day All-cause Mortality — 302; 289 participants — p=0.47
Phase 2 N=24 Nutrition, Inflammation and Insulin Resistance in End Stage Renal Disease-Aim 2
ESRD
Primary: Change in Leucine Disposal Rate (LDR) — -0.011; 0.005; 0.001 mg/kg/min — p=0.37
N/A N=1,113 Renal Replacement Therapy and In-Hospital Mortality Incidence in Cardiac Surgery Associated Acute Kidney Injury
Acute Kidney Injury
Primary: Mortality — 96; 34 Participants — p=<0.0001
Phase 3 N=1,228 A Study of Intravenous or Subcutaneous Methoxy Polyethylene Glycol-Epoetin Beta (RO0503821, Mircera) in Chronic Kidney Disease Patients With Renal Anemia
Anemia
Primary: Change From Baseline in Hemoglobin Concentration to the Last Month of Study Participation — -0.55; -0.38 g/dL
Phase 3 N=13 Belatacept Therapy for the Failing Renal Allograft
Failing Renal Allograft
Primary: Number of Participants With Donor-specific Antibody Formation — 3; 4 Participants
N/A N=234 Empowering Patients On Choices for Renal Replacement Therapy (Aim 3) (EPOCH-RRT)
Chronic Kidney Disease
Primary: Preference for Shared Decision Making — 22; 19; 35; 44 participants
Phase 3 N=603 A Study of Treatment With NeoRecormon (Epoetin Beta) in Patients With Chronic Renal Anemia
Anemia
Primary: Median Time to First Cardiovascular Event — NA; NA days — p=0.2036
Phase 3 N=836 Roxadustat in the Treatment of Anemia in End Stage Renal Disease (ESRD) Patients on Stable Dialysis
Anemia · End Stage Renal Disease (ESRD)
Primary: Change From Baseline (BL) to the Average Hemoglobin (Hb) in Weeks 28-36 Without Rescue Therapy [EU (EMA)] — 0.428; 0.193 g/dL — p=<0.001
Phase 2 N=58 Regimen Optimization Study
Kidney Transplantation
Primary: Percentage of Clinically-suspected Biopsy-proven Acute Rejection (CSBPAR) at 6 Months — 7.7; 9.4 Percentage of participants
Phase 3 N=947 Benefits of Medical Therapy Plus Stenting for Renal Atherosclerotic Lesions
Atherosclerosis · Cardiovascular Diseases · Hypertension, Renovascular
Primary: Composite Endpoint: Death From Cardiovascular or Renal Causes, Stroke, Myocardial Infarction, Hospitalization for CHF, Progressive Renal Insufficiency, or Permanent…
Phase 2 N=27 Treatment of Hypoparathyroidism With Synthetic Human Parathyroid Hormone 1-34
Hypoparathyroidism
Primary: Serum Calcium Level — 2; 1.92 mmol/liter
Phase 2 N=18 A Study in Participants With End-Stage Renal Disease
Kidney Failure, Chronic
Primary: Change From Baseline in PRA — -0.706; -2.176; -1.688; -2.353 percentage of population — p=0.324
N/A N=104 IV Insulin Protocol in Diabetes and Renal Transplantation
Kidney Transplantation · Diabetes · Hyperglycemia
Primary: Delayed Graft Function — 8; 12 participants
Phase 3 N=114 Treatment of Autonomous Hyperparathyroidism in Post Renal Transplant Recipients
Chronic Allograft Nephropathy · Chronic Kidney Disease · Chronic Renal Failure
Primary: Percentage of Participants With a Mean Corrected Total Serum Calcium Value < 10.2 mg/dL (2.55 mmol/L) During the Efficacy Assessment Phase (EAP) — 3.5; 78.9 percentage…
Phase 1 N=19 RENABLATE-II Feasibility Study of Catheter Based Renal Denervation to Treat Resistant Hypertension - 157
Hypertension, Renal
Primary: Incidence of Major Adverse Events That Occurred Within 30 Days Post-procedure. — 0.0 percentage of participants
Phase 4 N=26 Panel Reactive Antibody (PRA) Reduction in Sensitized Patients Awaiting Renal Transplantation
End Stage Renal Disease
Primary: The Percent of Sensitized Patients Treated With PRA Reduction Pharmacological Therapy, Including Cytogam, Who Become Cross-match Compatible With Potential Living Donor…
N/A N=141 Renal Osteodystrophy: An Individual Management Approach
Kidney Failure, Chronic
Primary: Change in Quantitative Computed Tomography (QCT) Bone Mineral Density of the Hip — -10.71; 5.72; -3.52; .2 g/cm^3 — p=.443
Phase 2 N=42 Randomized Trial of Risedronate to Prevent Bone Loss in Renal Transplant Recipients.
Renal Transplant Osteodystrophy
Primary: Bone Mineral Density of Spine at 6 Months — 0.98; 0.97 gm/cm^2
Phase 3 N=233 A Study of Subcutaneous Mircera for the Maintenance Treatment of Dialysis Patients With Chronic Renal Anemia.
Anemia
Primary: Percentage of Participants Maintaining Their Mean Hemoglobin Concentration Within Plus or Minus 1 Gram/Deciliter of Their Reference Hemoglobin and Between the Target…